Core Viewpoint - The AI healthcare sector is experiencing significant growth and interest in 2026, with the AI healthcare index rising over 11% in just 14 trading days, indicating a clear trend in capital market enthusiasm for this sector [1][2]. Market Performance - As of January 22, 2026, the AI healthcare index increased by over 11%, while the CSI Medical Index and Hang Seng Healthcare Index rose by 7.68% and 10.65%, respectively [1]. - Companies like Di'an Diagnostics and Baolait have seen their stock prices surge over 60%, with others like Weining Health and Chengdu Xian Dao also experiencing gains exceeding 30% [1]. Industry Growth Projections - According to Frost & Sullivan, the AI healthcare market in China is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate (CAGR) of 43.1% [1]. Technological Advancements - Major tech companies are actively entering the AI healthcare space, with OpenAI launching a healthcare version of ChatGPT and other firms like Ant Group, Tencent, JD, and ByteDance developing AI healthcare models and applications [5][6]. - AI drug development is identified as the fastest-growing segment within AI healthcare, with companies like Insilico Medicine and WuXi AppTec significantly reducing drug development timelines [6][7]. Commercialization Challenges - Despite the enthusiasm, the commercialization of AI healthcare products is facing challenges, with many companies reporting losses. For instance, 24 out of 47 biomedicine companies forecasted losses or reduced profits for 2025 [10]. - Companies like KingMed Diagnostics and Anbiping are experiencing significant revenue declines, with Anbiping reporting a 28.29% drop in revenue year-on-year [10][11]. Regulatory Developments - Recent government policies are seen as a positive signal for the AI healthcare sector, with initiatives aimed at promoting and standardizing AI applications in healthcare [15][16]. - The National Healthcare Security Administration has clarified pricing for AI-assisted diagnostic services, which is expected to facilitate the integration of AI into routine clinical practice [15][16]. Future Outlook - Industry experts predict that 2026 will be a pivotal year for AI healthcare, with clearer payment structures and stronger financial backing expected to enhance commercialization prospects [16].

Core Viewpoint - The market is experiencing significant differentiation as of Q4 2025, with a focus on the balance between returns, cycles, and risks rather than just the correctness of investment directions [1] Group 1: Fund Manager Insights - Fund manager Yao Zhipeng has been with Harvest Fund since 2011, focusing on growth and industry directions, and has extensive experience managing various product types [1][2] - The total scale of products managed by Yao Zhipeng is approximately 20 billion yuan, with Harvest Power Pioneer being a representative product [2] Group 2: Portfolio Composition - The top ten holdings of Harvest Power Pioneer include Ningde Times, Xinda Bio, Hunan Youneng, WuXi AppTec, O-film Tech, Zhongkuang Resources, Putailai, Nongfu Spring, Tianqi Lithium, and Xiaopeng Motors, indicating a multi-line structure [2][3] - The portfolio is built on three clear lines: 1. New energy, lithium battery, and new energy vehicle industry chain [3] 2. Pharmaceutical and innovative assets, reflecting ongoing attention to the innovative drug industry chain [3] 3. Consumer goods, with Nongfu Spring being one of the few hundred billion-level products in the food and beverage sector [4] Group 3: Market Environment Analysis - The overall market in Q4 2025 is characterized by a steady rise, with good returns in commercial aerospace, copper and aluminum commodities, chemicals, communications, and insurance, while cyclical assets have adjusted [4][5] - Yao Zhipeng expresses a cautious and neutral stance on the technology sector, highlighting the crowded nature of tech investments and the reevaluation of risks associated with AI [5][6] Group 4: Economic Outlook and Investment Strategy - The primary task for the Chinese economy in 2026 is to expand domestic demand, which will likely influence investment directions [6][7] - Long-term favored directions include new energy, new technology, new consumption, and innovative drugs, focusing on lithium batteries, embodied intelligent applications, and consumer assets that align with improving consumption [7] - Attention is also drawn to the potential for foreign capital inflow due to the appreciation of the RMB and the attractiveness of leading companies in various industries [8][9] Group 5: Portfolio Adjustment Strategy - Yao Zhipeng plans to gradually increase allocations to domestic demand and cyclical leading assets, enhancing the balance of the portfolio while dynamically adjusting based on macro and mid-level environmental changes [8][9]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical and healthcare innovation sector, with the China Medical and Medical Device Innovation Index rising by 0.87% and several key stocks showing significant gains [1] - Over 50 biopharmaceutical companies have disclosed their 2025 performance forecasts, with nearly half (27 companies) expecting positive results, indicating a favorable outlook for the sector [1] - The CXO (Contract Research Organization) industry, particularly leading company WuXi AppTec, is projected to achieve approximately 45.46 billion yuan in revenue for 2025, reflecting a year-on-year growth of about 15.84%, and a net profit increase of approximately 102.65% [1] Group 2 - The National Healthcare Security Administration has introduced new policies to accelerate the promotion and adoption of surgical robots and related surgical consumables, which is expected to benefit the overall innovative medical device market [2] - Investors are advised to focus on two main investment themes: the surgical robot industry and its supply chain, as well as high-value consumables in minimally invasive surgery, orthopedics, gastroenterology, cardiovascular, and neurology [2] - The China Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability and growth potential, with the top ten stocks accounting for 63.75% of the index [2]

一、债市要闻 （一）国内要闻 【央行行长潘功胜：继续维护好金融市场平稳运行，支持资本市场稳定发展】1月22日，央行行长潘功胜在接受 采访时表示，2026年，央行将继续实施好适度宽松的货币政策，把促进经济稳定增长、物价合理回升作为货币 政策的重要考量，发挥增量政策和存量政策集成效应，为经济稳定增长、高质量发展和金融市场稳定运行营造 良好的货币金融环境，为实现"十五五"良好开局提供有力的金融支撑。潘功胜谈到，总量政策方面，灵活高效运 用降准降息等多种货币政策工具，保持流动性充裕，使社会融资规模、货币供应量增长同经济增长、价格总水 平预期目标相匹配。今年降准降息还有一定的空间。央行还将做好利率政策执行和监督，促进社会综合融资成 本低位运行。结构性政策方面，央行已在今年年初先行出台一批货币金融政策，对结构性货币政策工具的政策 要素作了优化完善。 【央行连续11个月加量操作MLF，加码中长期资金投放】央行1月22日发布中期借贷便利招标公告称，为保持银 行体系流动性充裕，1月23日，将以固定数量、利率招标、多重价位中标方式开展9000亿元中期借贷便利 （MLF）操作，期限为1年期。鉴于本月2000亿元MLF到期，央行1月 ...

Group 1 - Leading private equity firms are increasing their positions, with stock private equity positions rising above 81% as of January 9, 2026, marking an increase of over 1 percentage point from the end of 2025 [1] - The first week of 2026 saw a significant increase in positions among large private equity firms, with an average increase of nearly 8 percentage points [1] - The capital market is expected to continue its structural trends in 2026, driven by reduced external uncertainties, low interest rates, and solidifying corporate earnings [1] Group 2 - The A-share market has seen a significant reduction in the total shares of major broad-based ETFs, indicating a major reallocation by the "national team" [2] - The latest public fund quarterly reports confirm that major ETFs like Huatai-PB CSI 300 ETF and Huaxia SSE 50 ETF have seen their total shares drop below the holdings of the central financial authority [2] Group 3 - Over 50 biopharmaceutical companies have released performance forecasts for 2025, with nearly half indicating positive expectations [3] - Leading CXO companies, such as WuXi AppTec, are projected to achieve significant revenue growth, with an expected revenue of approximately 45.46 billion yuan, a year-on-year increase of about 15.84% [3] - The biopharmaceutical industry is anticipated to enter a new phase of high-quality development in 2026, supported by ongoing policy and financing improvements [3] Group 4 - The gold jewelry market is experiencing a shift from weight-based pricing to value-based pricing, with brands introducing fixed-price products that appeal to younger consumers [4] - Upstream companies are benefiting from rising gold prices, which are expected to enhance profitability [4] Group 5 - The commercial space sector in China is entering a new phase focused on large-scale launches and commercial viability, with significant advancements expected in the next 3 to 5 years [5] - In 2025, China's commercial space sector completed 50 launches, accounting for 54% of total space launches, indicating a rapid acceleration in commercialization [5] Group 6 - The domestic GPU manufacturer, Shanghai Suiruan Technology, has received approval for its IPO on the Sci-Tech Innovation Board, aiming to raise 6 billion yuan [6] - The company is part of a growing trend of domestic tech firms seeking public funding to support their growth [6]

Core Viewpoint - The article emphasizes China's dominant position in the global pharmaceutical supply chain, particularly in the production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), which poses a significant asymmetric threat to U.S. national security [3][4][10]. Group 1: China's Dominance in Pharmaceutical Supply Chain - China holds a near-monopoly in several key areas of pharmaceutical production, including over 90% of global antibiotic intermediates and 70%-80% of vitamin production capacity [13][10]. - The U.S. and Europe dominate patented and biological drugs, while India is known as the "world's pharmacy" for its large-scale production of generic drugs, but it relies heavily on China for approximately 70% of its active ingredients and intermediates [10][22]. - The integration of China's chemical industry has created significant cost advantages, with production costs being 30%-40% lower than those in Europe and the U.S., and even 20% lower than in India [15][18]. Group 2: Implications of Supply Chain Dependency - The U.S. faces a critical dependency on Chinese pharmaceutical supplies, which could lead to severe shortages in essential medications, as highlighted by potential disruptions in supply chains due to geopolitical tensions [4][6]. - The FDA's reports indicate ongoing drug shortages in the U.S., exacerbated by the complex and often misleading nature of pharmaceutical supply chains, where active ingredients may originate from various countries, including China [6][7]. - The article warns that the "asymmetric interdependence" between the U.S. and China in the pharmaceutical sector could lead to significant vulnerabilities for the U.S. healthcare system [4][6]. Group 3: Future Outlook and Strategic Considerations - As the U.S. pushes for decoupling from China, the article suggests that rebuilding a lost industrial base in pharmaceuticals will be a long and challenging process, requiring a new generation of skilled engineers and a cultural shift towards accepting chemical manufacturing [29][30]. - The article posits that while China currently holds a strategic advantage, it must remain vigilant against emerging technologies in biomanufacturing that could disrupt its dominance [30]. - The future of the pharmaceutical industry will hinge on balancing efficiency and safety, with the ability to provide lower-cost, safer drugs being a key competitive factor [31].

Short Selling Ratios - China Resources Beer (80291) and JD Group (89618) have the highest short selling ratios at 100.00% each, followed by Lenovo Group (80992) at 95.62% [1] - The top ten short selling ratios include Li Ning (82331) at 93.21% and Anta Sports (82020) at 88.46% [1] Short Selling Amounts - Alibaba (09988) leads in short selling amount with 1.173 billion, followed by Baidu (09888) at 1.111 billion and Pop Mart (09992) at 1.049 billion [1] - Other notable companies in the top ten include Meituan (03690) at 814 million and China Life (02628) at 806 million [1] Deviation Values - JD Group (89618) has the highest deviation value at 37.56%, followed by China Ping An (82318) at 33.98% and China Huaneng (03788) at 33.27% [1] - Other companies with significant deviation values include SenseTime (80020) at 32.05% and Li Ning (82331) at 31.52% [1]

Group 1: Commercial Aerospace - The Chinese commercial aerospace sector is entering a new phase aimed at large-scale launches and commercial closed-loop systems, with significant breakthroughs expected in rocket capacity over the next 3 to 5 years [1] - By 2025, China's commercial aerospace is projected to complete 50 launches, accounting for 54% of total space launches, with 25 commercial rockets launched and 311 commercial satellites in orbit, representing 84% of total satellites [1] - The capital market for commercial aerospace companies is accelerating, with several leading firms preparing for IPOs, including Blue Arrow Aerospace and Zhongke Aerospace [1] Group 2: Public Fund Performance - The latest public fund reports reveal that the top ten holdings include companies like Zhongji Xuchuang, Ningde Times, and Tencent, with notable increases in holdings for companies like Zhongji Xuchuang, which saw an increase of 22.602 billion yuan [2] - The automotive industry is facing cost pressures due to rising prices of memory chips and metals, impacting supply chain dynamics and competition [2] Group 3: Biopharmaceutical Industry - Over 50 biopharmaceutical companies have disclosed their 2025 performance forecasts, with nearly 50% showing positive expectations, particularly in the CXO sector, where WuXi AppTec anticipates a revenue increase of approximately 15.84% [3] - The biopharmaceutical industry is expected to enter a new phase of high-quality development as structural reforms and supportive policies continue to evolve [3] Group 4: Fundraising and Market Trends - The public fund market has seen a resurgence, with several equity funds raising over 7 billion yuan, indicating a positive trend in active equity fund performance [4] - The Shanghai Suiruan Technology Co., Ltd. has received approval for its IPO, aiming to raise 6 billion yuan for product development and business expansion [5] Group 5: Aluminum Market - The aluminum market has shown strong performance, with prices rising over 12% since mid-December 2025, supported by favorable macroeconomic conditions and demand for aluminum in various applications [6] - The copper-aluminum price ratio exceeding 4 suggests a potential shift towards aluminum in sectors like air conditioning, indicating new demand growth [6] Group 6: Banking Sector - Five listed banks have reported a year-on-year increase in net profit for 2025, with improvements in non-performing loan ratios for three banks [9] - The banking sector is expected to maintain stable performance, supported by improved funding costs and a potential stabilization of net interest margins [9] Group 7: Chemical Industry - The chemical industry is experiencing positive performance, with over 60% of companies reporting improved earnings, driven by rising prices of certain chemical products [10] - The DOP market is expected to maintain upward momentum due to strong raw material prices and limited supply, indicating a stable support for pricing [10]

● 本报记者 李梦扬 根据同花顺iFinD数据，截至1月22日记者发稿时，按照申万一级行业划分，已有逾50家生物医药企业披 露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括 CDMO和CRO）公司业绩表现亮眼。其中，CXO行业龙头药明康德预计2025年实现营业收入约454.56亿 元，同比增长约15.84%；实现归母净利润约191.51亿元，同比增长约102.65%。 业内人士表示，随着全球投融资逐步恢复、国内对创新药行业的持续支持以及新药研发逐步回暖， CXO产业趋势向好。2026年，随着行业结构性改革深化、政策与融资环境持续优化，中国医药产业提 质升级趋势明确，行业将迈向高质量发展新阶段。 27家生物医药公司业绩预喜 在已披露业绩预告的超50家生物医药公司中，27家预喜，其中，18家预增，5家略增，4家扭亏。从归母 净利润金额看，药明康德预计2025年实现归母净利润191.51亿元，位居第一；以岭药业、甘李药业、兴 齐眼药、华邦健康等公司居前，预计归母净利润下限均超5亿元。 剔除扭亏影响，从归母净利润同比变动下限看，上海谊众、康辰药业、特一药业、昭衍新药等多家 ...

Group 1 - The A-share market experienced fluctuations at relatively high levels in Q4 2025, with a slight decrease in overall equity positions of public funds compared to Q3 2025 [1][2] - The average equity positions for stock and mixed funds were 89.06% and 81.05%, respectively, showing a minor decline from the previous quarter [2] - Major holdings in public funds included leading light module companies, with Zhongji Xuchuang and Xinyi Sheng surpassing Ningde Times and Tencent Holdings to become the top two heavyweights [1][4] Group 2 - Several actively managed equity funds significantly increased their positions, with notable examples including Bosera Huixing and GF Chengxiang, which raised their equity positions by 12.31 and 10.3 percentage points, respectively [2] - Fund managers expressed optimism about the A-share market for 2026, citing potential dual benefits from domestic and international liquidity [3][9] - The focus on technology sectors continued, with managers identifying investment opportunities in storage chips, solid-state batteries, and humanoid robots [7][10] Group 3 - The top 50 heavyweights in public funds were primarily concentrated in information technology, consumer goods, and investment sectors, with 18 stocks in the information technology sector [4][6] - AI-related stocks gained prominence, with Zhongji Xuchuang, Xinyi Sheng, and Hanwujing entering the top seven heavyweights due to the AI boom [4][6] - The number of innovative drug companies in the top 50 heavyweights decreased from eight to five by the end of Q4 2025, indicating a shift in investment focus [5] Group 4 - Fund managers anticipate that the AI investment theme will continue to be a primary focus, with expectations for rapid growth in AI applications in the coming years [9][10] - The investment strategy is shifting towards AI applications, including smart driving, edge AI, and humanoid robots, as the industry matures [9][10] - The overall sentiment among fund managers is that the AI-driven technology market will remain a significant area of investment for the next several years [9][10]